Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1

Go back to Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
(NASDAQ: BBIO) Delayed: 67.74 --0 (-0%)
Previous Close $67.74    52 Week High $ 
Open $67.74    52 Week Low $ 
Day High $67.74    P/E N/A 
Day Low $67.74    EPS $ 
Volume 8